<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
>

<channel>
	<title>News on Naglazyme from BioPortfolio.com</title>
	<link>http://www.BioPortfolio.com</link>
	<description>Consolidated Naglazyme news from BioPortfolio.com</description>
	<pubDate>Wed, 10 Feb 2010 14:47:29 GMT</pubDate>
	<language>en</language>
<atom:link href="http://www.bioportfolio.co.uk/cgi-bin/rssnews.pl?q=Naglazyme" rel="self" type="application/rss+xml" />

	
<item><title>BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4025434&amp;HITNO=0&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4025434&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2529767142%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4025434&amp;HITNO=0&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4025434&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2529767142%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>Biomarin To Buy LEAD For $97M, Gives 2010 Outlook</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4024892&amp;HITNO=1&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4024892&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2529257399%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4024892&amp;HITNO=1&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4024892&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2529257399%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>BioMarin reports preliminary data on BMN 110 for Morquio A Syndrome</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4024483&amp;HITNO=2&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4024483&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528923792%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4024483&amp;HITNO=2&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4024483&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528923792%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Therapeutics Daily:</description></item>
<item><title>BioMarin reports preliminary data on BMN 110 for Morquio A Syndrome</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023926&amp;HITNO=3&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023926&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528489485%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023926&amp;HITNO=3&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023926&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528489485%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharmacy Choice:</description></item>
<item><title>BioMarin Announces 2010 Guidance</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023387&amp;HITNO=4&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023387&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528195484%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023387&amp;HITNO=4&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023387&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528195484%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Pharma Live:</description></item>
<item><title>BioMarin Announces 2010 Guidance</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023326&amp;HITNO=5&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023326&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528161537%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4023326&amp;HITNO=5&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4023326&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2528161537%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>SmartBrief:</description></item>
<item><title>BioMarin Announces 2010 Guidance</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018018&amp;HITNO=6&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018018&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525428483%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018018&amp;HITNO=6&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018018&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525428483%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Phoenix Business Journal:</description></item>
<item><title>BioMarin Announces 2010 Guidance</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4017975&amp;HITNO=7&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4017975&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525405060%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4017975&amp;HITNO=7&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4017975&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525405060%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Yahoo! Canada:</description></item>
<item><title>BioMarin to buy LEAD for $97M, gives 2010 outlook</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4021006&amp;HITNO=8&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4021006&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2527087780%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4021006&amp;HITNO=8&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4021006&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2527087780%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Research &amp; Development:</description></item>
<item><title>BioMarin Pharma says it will buy cancer drug maker, and gives 2010 forecasts and study update</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4020967&amp;HITNO=9&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4020967&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2527077001%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4020967&amp;HITNO=9&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4020967&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2527077001%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>DCExaminer.com:</description></item>
<item><title>BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018974&amp;HITNO=10&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018974&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2526027387%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018974&amp;HITNO=10&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018974&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2526027387%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>News-Medical.Net:</description></item>
<item><title>BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018066&amp;HITNO=11&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018066&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525456322%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018066&amp;HITNO=11&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018066&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525456322%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Los Angeles Business:</description></item>
<item><title>BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018023&amp;HITNO=12&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018023&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525432716%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018023&amp;HITNO=12&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018023&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525432716%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Nashville Business Journal:</description></item>
<item><title>BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018016&amp;HITNO=13&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018016&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525424826%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4018016&amp;HITNO=13&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4018016&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525424826%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Phoenix Business Journal:</description></item>
<item><title>BioMarin Reports Encouraging Preliminary Data on BMN 110 for MPS IVA</title><link>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4017980&amp;HITNO=14&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4017980&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525405929%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</link><guid>http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&amp;ID=4017980&amp;HITNO=14&amp;MSIZE=116&amp;LANGUAGE=en&amp;FILE=doc.NEWSFEED&amp;SAVEQUERY00=Naglazyme&amp;SAVEPROP00=L%3den&amp;SAVEDB=news&amp;SAVEORGANISE_CODED=R:date&amp;R=4017980&amp;THISHREF=http://c.moreover.com/click/here.pl%3fz2525405929%26amp%3bz%3d950242273&amp;THEHOST=site+d.moreover.com</guid><description>Yahoo! Canada:</description></item>
</channel></rss>